Released Nov 4, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-050755
Q3 2020 · 10-Q
Revenue$17.82M$17.82M +45.2% vs Q3 2019+88.2% vs Q2 2020
Net Income$17.14M$17.14M N/M vs Q3 2019−42.6% vs Q2 2020
EPS Diluted$0.45$0.45 N/M vs Q3 2019−52.1% vs Q2 2020
Operating Income-$10,617,000N/M
Operating Cash Flowderived-$17,689,000N/M
Margins · derived
Operating margin-59.6%+44.2 pt vs Q3 2019
Net margin96.2%+201.3 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $17.82M | $12.28M | $7.84M | $17.50M |
| Net Income | $17.14M | -$12.91M | -$10.24M | -$1.42M |
| EPS Diluted | $0.45 | -$0.56 | -$21.26 | -$3.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR